Live Quote · NASDAQMIRMHealthcare· Biotechnology

Mirum Pharmaceuticals, Inc.

$118.86▲ 1.28%(+$1.50)
TickerSpark Score
74/100
▌ Solid
55
Valuation
40
Profitability
100
Growth
76
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MIRM research report →

52-Week Range86% of range
Low
$50.25
Current
$118.86
High
$130.00
Company Overviewwww.mirumpharma.com

About the company

Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.

CEO
Christopher Peetz
IPO
2019
Employees
418
HQ
Foster City, CA, US

Price Chart

+125.41% · this period
$128.57$89.84$51.12Jul 17Jan 15Jul 17

Get TickerSpark's AI analysis on MIRM

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in